Preferred Label : ledipasvir;

MeSH synonym : ledipasvir acetonate; methyl ((1S)-1-((1R,3S,4S)-3-(5-(9,9-difluoro-7-(2-((6S)-5-(N-(methoxycarbonyl)- l-valyl)-5-azaspiro(2.4)hept-6-yl)-1H-imidazol-4-yl)-9H-fluoren-2-yl)-1H-benzimidazol-2-yl)-2-azabicyclo(2.2.1)heptane-2-carbonyl)-2-methylpropyl)carbamate;

MeSH hyponym : GS5885;

UNII : 013TE6E4WV;

InChIKey : VRTWBAAJJOHBQU-KMWAZVGDSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3299667/fr/harvoni-sofosbuvir/-ledipasvir
2021
false
false
false
France
evaluation of the transparency committee
ledipasvir
ledipasvir
outcome studies
Harvoni
ledipasvir
registries
Outcome Assessment, Health Care
resulting in

---
https://www.has-sante.fr/jcms/p_3152635/fr/harvoni
2020
false
false
false
France
Sofosbuvir
treatment outcome
ledipasvir
ledipasvir, sofosbuvir drug combination
adult
adolescent
antiviral agents
drug combinations
hepatitis C, chronic
evaluation of the transparency committee
Harvoni
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni-sofosbuvir/ledipasvir-antiviral-a-action-directe
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni
2018
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
guidelines for drug use
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
adolescent
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-juin-Recommandations-AFEF-Hepatite-C.pdf
2016
false
false
true
false
France
French
hepatitis C, chronic
practice guideline
severity of illness index
hepatitis C, chronic
antiviral agents
comorbidity
genotype
daclatasvir
ledipasvir
ribavirin
treatment outcome
drug resistance, viral
pregnancy
patient education as topic
liver cirrhosis
liver transplantation
recurrence
renal insufficiency
child
adolescent
drug users
hiv infections
acute disease
Acute hepatitis C
Simeprevir
Sofosbuvir
ledipasvir
ledipasvir, sofosbuvir drug combination
daclatasvir
imidazoles
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni-sofosbuvir/ledipasvir-association-fixe-dantiviraux-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
adult
guidelines for drug use
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 3 (organism)
Hepatitis C virus genotype 4 (organism)
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
https://www.ema.europa.eu/medicines/human/EPAR/Harvoni
2014
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
adult
hepatitis C, chronic
administration, oral
tablets
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
NS-5b protein, hepatitis C virus
treatment outcome
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
viral nonstructural proteins
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
Nous contacter.
25/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.